Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Mufg Securities Americas Inc. made a modest splash in the biotech pool, acquiring 1,554 shares of Regeneron Pharmaceuticals ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Analysts at Leerink agreed with Sanofi that ... This matches or exceeds the performance of Sanofi and Regeneron’s prized drug Dupixent and Amgen and AstraZenca’s Tezspire—two products that are ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...

The acquisition could save Bristol future profit-sharing costs in Abecma, according to Leerink analyst David Risinger. Last year, 2seventy sold all its experimental cell therapies to Regeneron ...

"Longer term, we believe that the FDA would require functional outcome benefits," Leerink analyst David Risinger ... watching Lilly's bimagrumab and Regeneron's trevogrumab now in mid-stage ...

Despite Opdualag’s failure in the adjuvant study, Leerink still expects Opdualag ... a LAG-3 antibody in development by Regeneron Pharmaceuticals. Fianlimab is in late-stage development as ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...